Progression estimates by protocol and GEP-70 risk. PFS and TTP are analyzed according to plasma cell GEP-based low- and high-risk subsets. Common to all endpoints examined, plateaus are reached earlier at ∼5 years in high-risk (B: PFS, D: TTP) compared with 10 years in the majority of 85% of patients with low-risk myeloma (A: PFS, C: TTP). (A) PFS by protocol: GEP-70 low-risk only. (B) PFS by protocol: GEP-70 high-risk only. (C) TTP: GEP-70 low-risk only. (D) TTP: GEP-70 high-risk only.